

Clopidogrel vs. Aspirin for Cardiovascular Risk Reduction in Patients With *S. Aureus* Bacteremia

NCT06650488

Status	RECRUITING
Phase	Phase 4
Sponsor	Todd C. Lee MD MPH FIDSA
Enrollment	300 participants

Key Eligibility Criteria

Inclusion (1)

- Patient is taking aspirin for secondary prevention of cardiovascular disease (coronary, cerebrovascular, or peripheral vascular disease)

Exclusion (6)

- Active bleeding (allowing up to 3 days from platform entry to randomize in the event anti-thrombotic therapy is resumed)
- Anticipated major cardiac surgery, neurosurgery, or spine surgery within the next 3 days
- Pregnancy
- Known receipt of clopidogrel, prasugrel, or ticagrelor within the last month
- Allergy to clopidogrel

... and 1 more (see full listing online)

Locations (1 total)

McGill University Health Centre (Royal Victoria Hospital and Montreal General Hospital), Montreal, Quebec, Canada